FDA authorises Comirnaty® booster dose for certain populations
The US FDA amended the emergency use authorisation to allow for a Comirnaty booster dose in individuals at high-risk for COVID-19.
List view / Grid view
The US FDA amended the emergency use authorisation to allow for a Comirnaty booster dose in individuals at high-risk for COVID-19.
Veklury (remdesivir) significantly reduced the risk of COVID-19 related hospitalisation and death in high-risk patients in Phase III study.
AstraZeneca will partner with VaxEquity for the discovery and development of a self-amplifying RNA (saRNA) therapeutics platform.
The Arctos Medical acquisition will expand Novarits’ optogenetics portfolio to bring gene therapies to patients with severe vision loss.
Johnson & Johnson announced Phase III data demonstrating effective COVID-19 protection and an increase in protection with a booster dose.
The next-generation active pharmaceutical ingredient manufacturing facility should meet the needs for AstraZeneca’s new medicines pipeline.
Xtandi reduced the risk of death by 34 percent in men with metastatic hormone sensitive prostate cancer in a Phase III study.
GSK announced multi-million renewable energy investment and low carbon inhaler programme in run-up to New York Climate Week.
Positive results from pivotal trial show that the COVID-19 vaccine Comirnaty is safe and effective in children aged five to 11 years old.
Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.
In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.
Kisqali plus letrozole achieved a median overall survival of over five years, the longest ever reported for HR+/HER2 breast cancer.
Trodelvy significantly improved overall survival and demonstrated clinically meaningful improvements in quality of life in Phase III study.
Sotorasib combined with panitumumab displayed 27 percent response rate against colorectal cancer in Phase I/II trial.
Ampion significantly reduced pain and improved function in severe osteoarthritis of the knee (OAK) in 12 weeks, shows Phase III study.